TALS Stock Price, Talaris Therapeutics, . Quote, Chart

Market Summary

USD2.72-0.02

Delayed

-0.73%

TALS Stock Price

View Fullscreen

TALS RSI Chart

TALS Valuation

Market Cap

73.3M

Price/Earnings (Trailing)

-1.74

Price/Free Cashflow

-2.61

TALS Price/Earnings (Trailing)

TALS Profitability

Return on Equity

-20.54%

Return on Assets

-20.03%

Free Cashflow Yield

-38.36%

TALS Fundamentals

TALS Revenue

TALS Earnings

Earnings (TTM)

-42.1M

Earnings Growth (Yr)

-94.04%

Earnings Growth (Qtr)

130.31%

Breaking Down TALS Revenue

Last 7 days

5.9%

Last 30 days

1.1%

Last 90 days

-6.8%

Trailing 12 Months

16.3%

How does TALS drawdown profile look like?

TALS Financial Health

Current Ratio

41.76

TALS Investor Care

Buy Backs (1Y)

51.26%

Diluted EPS (TTM)

-4.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Talaris Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 03, 2023	fenton mary kay	sold (taxes)	-39,873	3.08	-12,946	chief financial officer
Jul 03, 2023	requadt scott	sold (taxes)	-36,300	3.08	-11,786	-
Jun 14, 2023	ildstad suzanne	sold	-32,243	2.4914	-12,942	-
Jun 13, 2023	ildstad suzanne	sold	-36,338	2.5576	-14,208	-
Jun 12, 2023	ildstad suzanne	sold	-43,725	2.5919	-16,870	-
Jun 09, 2023	ildstad suzanne	sold	-62,637	2.4642	-25,419	-
Jun 08, 2023	ildstad suzanne	sold	-100,772	2.4795	-40,642	-
Jun 07, 2023	ildstad suzanne	sold	-179,095	2.3879	-75,001	-
Jun 06, 2023	ildstad suzanne	sold	-64,595	2.5283	-25,549	-
Jun 05, 2023	ildstad suzanne	sold	-19,754	2.5194	-7,841	-

Which funds bought or sold TALS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-5,409	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-3,092,760	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-245,735	-	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-50,000	-	-%
Feb 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-8,298,290	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-183,909	-	-%
Feb 14, 2024	Avoro Capital Advisors LLC	sold off	-100	-1,405,000	-	-%
Feb 14, 2024	TWO SIGMA ADVISERS, LP	sold off	-100	-636,822	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-51,755	-	-%
Feb 14, 2024	RA CAPITAL MANAGEMENT, L.P.	sold off	-100	-6,753,100	-	-%

Are Funds Buying or Selling TALS?

Are funds buying TALS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TALS

No. of Funds

Unveiling Talaris Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	pfizer inc	4.96%	1,272,214	SC 13G/A
Feb 14, 2024	blue owl capital holdings lp	6.55%	1,332,302	SC 13G
Feb 14, 2024	hydra llc	6.6%	1,702,164	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	5.9%	1,477,593	SC 13G
Feb 09, 2024	blackstone holdings ii l.p.	0%	0	SC 13G/A
Feb 07, 2024	bml investment partners, l.p.	1.0%	245,500	SC 13G/A
Nov 06, 2023	hydra llc	5.9%	1,202,164	SC 13G
Oct 30, 2023	longitude capital partners iii, llc	1.6%	322,077	SC 13D/A

Recent SEC filings of Talaris Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Mar 19, 2024	10-K	Annual Report
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 15, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Talaris Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-0.89%	-25.81%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-9.98	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.68	3.85	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.94%	-8.31%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-12.98%	-52.88%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	7.90%	326.47%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-13.94%	-3.10%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	63.30%	36.92%	-0.23	2.14	-13.45%	66.37%

Talaris Therapeutics, Inc. News

Latest updates

Talaris Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Revenue	-	538	-	-	-	-
Operating Expenses	-42.6%	9,470	16,502	24,078	-36,951	19,823
S&GA Expenses	51.2%	9,114	6,026	6,182	-12,113	4,842
R&D Expenses	-97.0%	267	8,800	13,415	-24,838	14,981
Net Income	52.4%	-7,015	-14,738	-22,497	35,665	-19,011
Free Cashflow	49.7%	-7,502	-14,919	-17,222	-14,182	-13,768

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	39.2%	210	151	159	173	190	207	221	237	251	261	273	145	153
Current Assets	38.3%	209	151	156	169	8.00	198	212	228	247	258	270	143	151
Cash Equivalents	109.8%	141	67.00	18.00	24.00	8.00	18.00	26.00	23.00	0.00	27.00	36.00	10.00	18.00
Net PPE	-	0.00	-	0.00	3.00	0.00	5.00	6.00	5.00	5.00	3.00	2.00	2.00	2.00
Liabilities	-35.8%	5.00	8.00	11.00	11.00	2.00	12.00	10.00	11.00	9.00	6.00	5.00	5.00	5.00
Current Liabilities	-38.3%	5.00	8.00	10.00	10.00	1.00	9.00	7.00	8.00	8.00	5.00	5.00	4.00	3.00
Shareholder's Equity	43.5%	205	143	148	162	180	195	211	226	243	256	267	-	-
Retained Earnings	70.3%	-62.05	-208	-201	-187	-19.93	-146	-127	-109	-90.85	-76.61	-63.70	-52.30	-43.01
Additional Paid-In Capital	-24.1%	267	352	351	349	0.00	342	339	336	334	332	331	6.00	5.00
Shares Outstanding	374.9%	20.00	4.00	43.00	42.00	-	4.00	41.00	41.00	40.00	25.00	17.00	7.00	-
Float	-	-	-	90.00	-	-	-	139	-	-	-	280	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	246.9%	11,021	-7,502	-14,698	-16,902	40,529	-13,427	-17,280	-16,280	-9,842	-10,129	-10,982	-9,047	-5,650	-4,826	-3,493	-5,243
Share Based Compensation	-125.0%	-312	1,248	1,174	3,659	-7,889	3,041	2,846	2,197	994	1,053	896	835	593	186	120	123
Cashflow From Investing	-258.1%	-88,418	55,929	8,919	27,410	-51,727	6,304	19,928	20,427	721	1,694	-100,132	1,330	-104,363	-13,048	3,566	-19,455
Cashflow From Financing	211336.5%	156,463	74.00	137	46.00	19,668	73.00	79.00	30.00	412	-551	137,522	17.00	-	-	-	-

TALS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 32,368	$ 17,526
General and administrative	13,041	2,175
Total operating expenses	45,409	19,701
Loss from operations	(45,409)	(19,701)
Other income, net	3,285	0
Net loss	$ (42,124)	$ (19,701)
Net loss per share, basic (usd per share)	$ (8.87)	$ (22.46)
Net loss per share, diluted (usd per share)	$ (8.87)	$ (22.46)
Weighted-average, common shares outstanding, basic (in shares)	4,747	877
Weighted-average, common shares outstanding, diluted (in shares)	4,747	877
Other comprehensive income
Unrealized gain on short-term investments	$ 67	$ 0
Comprehensive loss	$ (42,057)	$ (19,701)

TALS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 140,726	$ 8,258
Short-term investments	62,225	0
Prepaid expenses and other current assets	5,923	54
Total current assets	208,874	8,312
Property and equipment, net	85	81
Restricted cash	227	216
Operating lease right-of-use asset	362	489
Other non-current assets	747	0
Total assets	210,295	9,098
Current liabilities
Accounts payable	1,071	401
Accrued expenses and other current liabilities	3,710	800
Operating lease liability, current portion	221	162
Total current liabilities	5,002	1,363
Operating lease liability, net of current portion	194	342
Other liabilities	57	0
Total liabilities	5,253	1,705
Commitments and Contingencies (Note 13)
Series A convertible preferred stock, $0.0001 par value – no shares authorized, issued or outstanding as of December 31, 2023; 27,125,000 shares authorized, issued and outstanding as of December 31, 2022	0	27,125
Stockholders’ equity (deficit)
Series A convertible preferred stock, $0.0001 par value – no shares authorized, issued or outstanding as of December 31, 2023; 27,125,000 shares authorized, issued and outstanding as of December 31, 2022	0	0
Common stock, $0.0001 par value – 140,000,000 voting shares authorized and 20,337,571 voting shares issued and outstanding as of December 31, 2023, 10,000,000 non-voting shares authorized and no non-voting shares issued or outstanding as of December 31, 2023; 50,000,000 shares authorized and 867,499 shares issued and outstanding as of December 31, 2022	2	0
Additional paid-in capital	267,024	195
Accumulated other comprehensive income	67	0
Accumulated deficit	(62,051)	(19,927)
Total stockholders’ equity (deficit)	205,042	(19,732)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 210,295	$ 9,098

About Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

CEO	Ms. Mary Kay Fenton
WEBSITE	https://talaristx.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Talaris Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Talaris Therapeutics, Inc.? What does TALS stand for in stocks?

TALS is the stock ticker symbol of Talaris Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Talaris Therapeutics, Inc. (TALS)?

As of Thu Feb 29 2024, market cap of Talaris Therapeutics, Inc. is 73.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TALS stock?

You can check TALS's fair value in chart for subscribers.

What is the fair value of TALS stock?

You can check TALS's fair value in chart for subscribers. The fair value of Talaris Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Talaris Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TALS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Talaris Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TALS is over valued or under valued. Whether Talaris Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Talaris Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TALS.